Get the Stockscreener App
1.93
3.02%
-0.06
After Hours:
1.91
-0.02
-1.04%
Senti Biosciences Inc stock is traded at $1.93, with a volume of 244.28K.
It is down -3.02% in the last 24 hours and down -5.85% over the past month.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
See More
Previous Close:
$1.99
Open:
$2.01
24h Volume:
244.28K
Relative Volume:
0.77
Market Cap:
$50.34M
Revenue:
$1.79M
Net Income/Loss:
$-70.90M
P/E Ratio:
-0.1242
EPS:
-15.54
Net Cash Flow:
$-34.95M
1W Performance:
-1.03%
1M Performance:
-5.85%
6M Performance:
-59.11%
1Y Performance:
-16.81%
1-Day Range:
$1.83
$2.01
1-Week Range:
$1.83
$2.12
52-Week Range:
$1.5201
$16.94
Senti Biosciences Inc Stock (SNTI) Company Profile
Name
Senti Biosciences Inc
Sector
Industry
Phone
(650) 382-3281
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
1.93 | 51.90M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Laidlaw | Buy |
| Oct-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Stock (SNTI) Latest News
What analysts say about Senti Biosciences Inc. stockPowerful profit generation - PrintWeekIndia
What drives Senti Biosciences Inc. stock priceHigh-yield trading alerts - Autocar Professional
What makes Senti Biosciences Inc. stock price move sharplyFree Stock Tips Group - Newser
Can Senti Biosciences Inc. stock recover from recent declineUnstoppable trading performance - jammulinksnews.com
Is Senti Biosciences Inc. a good long term investmentAccelerated capital growth - jammulinksnews.com
Senti Biosciences Inc. Stock Analysis and ForecastFree Consultation - jammulinksnews.com
Senti Biosciences Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
Exclusive: Senti Bio CEO Reveals Personal Journey and Strategic Vision for Gene Circuit Platform - Stock Titan
Quipt Home Medical: Top 10 Undervalued Medical Distribution Industry Stocks (QIPT) - The Globe and Mail
Solid Biosciences Inc. shares rise 3.29% premarket after Senti Bio's presentation at BioScience Forum. - AInvest
Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum - The Manila Times
Senti Bio to present logic-gated CAR-NK cell therapy at BioScience Forum - Investing.com
Why Senti Biosciences Inc. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - beatles.ru
Senti Bio Appoints Bryan Baum to Board of Directors, Aims for Growth with New Expertise. - AInvest
Senti Biosciences Appoints Bryan Baum to Board, Enhancing Strategic Direction and Optimizing Value for Stakeholders - AInvest
Bryan Baum Joins Senti Biosciences Board of Directors - AInvest
Sweetgreen, Inc. shares rise 3.77% intraday after Senti Biosciences, Inc. appoints Bryan Baum to its Board of Directors. - AInvest
Senti Biosciences Appoints Bryan Baum to Board - TipRanks
Senti Bio appoints K5 Global co-founder Bryan Baum to board of directors By Investing.com - Investing.com South Africa
Senti Bio appoints K5 Global co-founder Bryan Baum to board of directors - Investing.com
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors - The Manila Times
Is Senti Biosciences Inc. stock overhyped or has real potentialLow Risk ROI Maximization - Newser
How Senti Biosciences Inc. stock performs during market volatilityStrong Buy Recommendations - Newser
SNTI’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Senti Biosciences Stock Faces Decline Amid Market Challenges - timothysykes.com
Senti Biosciences Soars 32.39% on Promising Clinical Trial Results - AInvest
Senti Biosciences (NASDAQ:SNTI) Upgraded by Wall Street Zen to “Sell” Rating - Defense World
Senti Biosciences (NASDAQ:SNTI) Trading Up 2.5% – Here’s What Happened - Defense World
Senti Biosciences Inc Stock (SNTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Senti Biosciences Inc Stock (SNTI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lu Timothy K | CEO |
Feb 06 '25 |
Sale |
4.36 |
545 |
2,376 |
82,082 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 04 '25 |
Sale |
4.07 |
1,297 |
5,279 |
8,803 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 06 '25 |
Sale |
4.37 |
182 |
795 |
8,621 |
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):